RU2013154355A - Способ лечения мезотелиомы ингибитором рi3к - Google Patents
Способ лечения мезотелиомы ингибитором рi3к Download PDFInfo
- Publication number
- RU2013154355A RU2013154355A RU2013154355/15A RU2013154355A RU2013154355A RU 2013154355 A RU2013154355 A RU 2013154355A RU 2013154355/15 A RU2013154355/15 A RU 2013154355/15A RU 2013154355 A RU2013154355 A RU 2013154355A RU 2013154355 A RU2013154355 A RU 2013154355A
- Authority
- RU
- Russia
- Prior art keywords
- gdc
- patient
- mesothelioma
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
1. GDC-0980, имеющий структуру:для применения для лечения мезотелиомы.2. Применение GDC-0980, имеющего структуру:для получения лекарственного средства для лечения мезотелиомы.3. Применение GDC-0980, имеющего структуру:для лечения мезотелиомы.4. Способ лечения мезотелиомы, включающий введение пациенту с мезотелиомой терапевтически эффективного количества GDC-0980, имеющего структуру:5. Способ по п. 4, когда пациент имеет злокачественную плевральную мезотелиому.6. Способ по п. 4, когда пациента ранее лечили химиотерапией, лучевой терапией и/или хирургической резекцией.7. Способ по п. 6, когда пациента ранее лечили одним или более чем одним химиотерапевтическим агентом, выбранным из пеметрекседа, бевацизумаба, цисплатина, гемцитабина, винорелбина, иматиниба, дазатиниба, эрлотиниба, сунитиниба и сорафениба.8. Способ по п. 4, в котором GDC-0980 вводится пациенту ежесуточно с интервалами три недели или четыре недели.9. Способ по п. 8, в котором после трехнедельного интервала следует однонедельный перерыв, когда пациенту не вводится GDC-0980.10. Способ по п. 4, в котором GDC-0980 вводится перорально.11. Способ по п. 4, в котором терапевтически эффективное количество GDC-0980 составляет от 1 мг до 100 мг в сутки на массу тела пациента.12. Способ по п. 4, в котором терапевтически эффективное количество GDC-0980 составляет от 10 мг до 50 мг в сутки в зависимости от массы тела пациента.13. Способ по п. 4, кроме того, включающий введение химиотерапевтического агента, выбранного из пеметрекседа, бевацизумаба, цисплатина, гемцитабина, винорелбина, иматиниба, дазатиниба, эрлотиниба, сунитиниба или сорафениба.14. Способ по п. 4, в котором GDC-0980 приготовлен в виде композиции с ингредиентом,
Claims (15)
5. Способ по п. 4, когда пациент имеет злокачественную плевральную мезотелиому.
6. Способ по п. 4, когда пациента ранее лечили химиотерапией, лучевой терапией и/или хирургической резекцией.
7. Способ по п. 6, когда пациента ранее лечили одним или более чем одним химиотерапевтическим агентом, выбранным из пеметрекседа, бевацизумаба, цисплатина, гемцитабина, винорелбина, иматиниба, дазатиниба, эрлотиниба, сунитиниба и сорафениба.
8. Способ по п. 4, в котором GDC-0980 вводится пациенту ежесуточно с интервалами три недели или четыре недели.
9. Способ по п. 8, в котором после трехнедельного интервала следует однонедельный перерыв, когда пациенту не вводится GDC-0980.
10. Способ по п. 4, в котором GDC-0980 вводится перорально.
11. Способ по п. 4, в котором терапевтически эффективное количество GDC-0980 составляет от 1 мг до 100 мг в сутки на массу тела пациента.
12. Способ по п. 4, в котором терапевтически эффективное количество GDC-0980 составляет от 10 мг до 50 мг в сутки в зависимости от массы тела пациента.
13. Способ по п. 4, кроме того, включающий введение химиотерапевтического агента, выбранного из пеметрекседа, бевацизумаба, цисплатина, гемцитабина, винорелбина, иматиниба, дазатиниба, эрлотиниба, сунитиниба или сорафениба.
14. Способ по п. 4, в котором GDC-0980 приготовлен в виде композиции с ингредиентом, выбранным из микрокристаллической целлюлозы, моногидрата лактозы, кроскармеллозы натрия, коповидона и стеарата магния.
15. Способ по п. 4, в котором GDC-0980 приготовлен в виде композиции с фармацевтически приемлемым скользящим веществом, выбранным из диоксида кремния, порошковой целлюлозы, микрокристаллической целлюлозы, стеаратов металлов, алюмосиликата натрия, бензоата натрия, карбоната кальция, силиката кальция, кукурузного крахмала, карбоната магния, талька, не содержащего асбест, стеаровета С, крахмала, крахмала 1500, лаурилсульфата магния, оксида магния и их комбинаций.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492966P | 2011-06-03 | 2011-06-03 | |
US61/492,966 | 2011-06-03 | ||
PCT/EP2012/060341 WO2012164060A1 (en) | 2011-06-03 | 2012-06-01 | Methods of treating mesothelioma with a pi3k inhibitor compound |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013154355A true RU2013154355A (ru) | 2015-07-20 |
Family
ID=46210240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013154355/15A RU2013154355A (ru) | 2011-06-03 | 2012-06-01 | Способ лечения мезотелиомы ингибитором рi3к |
Country Status (11)
Country | Link |
---|---|
US (1) | US20120308562A1 (ru) |
EP (1) | EP2714046A1 (ru) |
JP (1) | JP2014515390A (ru) |
KR (1) | KR20140040728A (ru) |
CN (1) | CN103582479A (ru) |
AR (1) | AR086647A1 (ru) |
BR (1) | BR112013030991A2 (ru) |
CA (1) | CA2835760A1 (ru) |
MX (1) | MX2013014151A (ru) |
RU (1) | RU2013154355A (ru) |
WO (1) | WO2012164060A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012082997A1 (en) | 2010-12-16 | 2012-06-21 | F. Hoffmann-La-Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
US8895729B2 (en) | 2012-10-10 | 2014-11-25 | Genentech, Inc. | Process for making thienopyrimidine compounds |
EP2999799A4 (en) * | 2013-05-23 | 2016-12-28 | Five Prime Therapeutics Inc | METHODS OF TREATING CANCER |
WO2014193912A1 (en) * | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
PT3079666T (pt) * | 2013-12-12 | 2021-02-18 | Almirall Sa | Composições farmacêuticas que contêm fumarato de dimetilo |
CN106999540B (zh) * | 2014-10-30 | 2020-10-27 | 比格基因有限公司 | 组合疗法 |
WO2017004122A1 (en) * | 2015-06-30 | 2017-01-05 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
WO2018234584A1 (en) | 2017-06-23 | 2018-12-27 | Almirall, S.A. | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE |
US11103594B2 (en) | 2018-02-01 | 2021-08-31 | Imam Abdulrahman Bin Faisal University | Hierarchical siliceous mesosilicalite nanocarrier loaded with platinum(II) complex |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
CN109053523B (zh) | 2005-10-07 | 2022-03-25 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
WO2008021385A2 (en) * | 2006-08-14 | 2008-02-21 | Sicor Inc. | Processes for preparing intermediates of pemetrexed |
AU2007329352B2 (en) | 2006-12-07 | 2013-01-17 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
TWI471134B (zh) * | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法 |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US9042479B2 (en) | 2008-10-16 | 2015-05-26 | Qualcomm Incorporated | Method and apparatus for avoiding interference between coexisting wireless systems |
US8536161B2 (en) | 2009-03-12 | 2013-09-17 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
-
2012
- 2012-06-01 KR KR1020137031910A patent/KR20140040728A/ko not_active Application Discontinuation
- 2012-06-01 MX MX2013014151A patent/MX2013014151A/es unknown
- 2012-06-01 BR BR112013030991A patent/BR112013030991A2/pt not_active IP Right Cessation
- 2012-06-01 JP JP2014513200A patent/JP2014515390A/ja active Pending
- 2012-06-01 CA CA2835760A patent/CA2835760A1/en not_active Abandoned
- 2012-06-01 RU RU2013154355/15A patent/RU2013154355A/ru not_active Application Discontinuation
- 2012-06-01 AR ARP120101945A patent/AR086647A1/es unknown
- 2012-06-01 WO PCT/EP2012/060341 patent/WO2012164060A1/en active Application Filing
- 2012-06-01 US US13/486,141 patent/US20120308562A1/en not_active Abandoned
- 2012-06-01 EP EP12726085.9A patent/EP2714046A1/en not_active Withdrawn
- 2012-06-01 CN CN201280027267.9A patent/CN103582479A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AR086647A1 (es) | 2014-01-15 |
MX2013014151A (es) | 2014-01-23 |
CA2835760A1 (en) | 2012-12-06 |
US20120308562A1 (en) | 2012-12-06 |
JP2014515390A (ja) | 2014-06-30 |
WO2012164060A1 (en) | 2012-12-06 |
BR112013030991A2 (pt) | 2016-11-29 |
EP2714046A1 (en) | 2014-04-09 |
KR20140040728A (ko) | 2014-04-03 |
CN103582479A (zh) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013154355A (ru) | Способ лечения мезотелиомы ингибитором рi3к | |
JP5911929B2 (ja) | 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬 | |
RU2016122609A (ru) | Составы соединений азаиндола | |
IL274393B (en) | Aggregates of frequent anti-her-2 antibody conjugates and co-therapeutic agents and methods of using them | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
MY141939A (en) | Pyridazine derivatives and their use as therapeutic agents | |
UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
NZ753904A (en) | Compositions and methods for treating anemia | |
UY32599A (es) | Formulación oral sólida de abt-263 | |
JP2014532704A5 (ru) | ||
AU2013341271A1 (en) | Combination therapy | |
DE602006017728D1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
CN111035640A (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
TW201529070A (zh) | 骨質疏鬆症治療劑 | |
RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
BR112015009504A2 (pt) | inibidores de rock | |
CN104434948B (zh) | 一种抗胰腺癌的药物组合物及其应用 | |
MX2023005078A (es) | Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
JP4091639B2 (ja) | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 | |
JP4322933B2 (ja) | チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および/または処置剤 | |
US9907797B2 (en) | Combination therapies for overcoming resistance to mitotic agents during chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160902 |